Recent case reports have indicated that haemorrhages-related adverse events may be associated with PARPis. However, little is known about the characteristics and signal strength factors of this kind of adverse event. Methods: A pharmacovigilance study from January 2004 to Ma...
One of these cells is a type of white blood cell called the “cytotoxic T cell,” which has the ability to kill damaged cells due to a virus or a tumor. Another type is the “natural killer cell,” a white blood cell that discharges some proteins and somehow “programs” infected cells...
aIt is hard to find a way out when you use other two person's logic in one paragraph 当您在一段时,使用其他二人逻辑发现出口是坚硬的[translate] aSD uPdate SD 更新[translate] aAppraising iniparib, the PARP inhibitor that never was--what must we learn? 评估 iniparib, PARP 抑制剂那没有是 ...
Drug resistanceClinical trialsDrug targetsAlthough the use of PARP inhibitors is a huge step forward, it is apparent that patients, both with and without BRCA-mutant ovarian cancer, will eventually become resistant to PARP inhibitors. Therefore, novel combination therapies may enhance PARP inhibitor ...
aINPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells. INPP4B overexpression在MDA-MB-231三倍消极乳腺癌细胞提高PARP抗化剂AG014699 antitumor效力。[translate] a2=Modify 5=Display 2=Modify 5=Display[translate] ...
Veliparib dihydrochloride, also known as ABT-888 dihydrochloride, is a potent inhibitor of PARP1 and PARP2 with Ki values of 5.2 nM and 2.9 nM, respectively, in cell-free assays. It is ineffective against SIRT2. So, what exactly is its biological activity and how can it be tested? Let'...
AML and MDS associated with PARP inhibitor treatment of ovarian cancer 2023, Gynecologic Oncology Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit: Focus in Ovarian Cancer 2024, International Journal of Molecular Sciences Poly(ADP-...
aPhase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. 口头PARP抗化剂olaparib与paclitaxel的组合为首先或二线病人治疗的阶段I试验有变形的三倍消极乳腺癌的。[translate] ...
Researchers say future studies should look at different classes of FDA-approved PARP1 inhibitor drugs as they may hold promise not just for Huntington disease but neurodegenerative diseases at large. Researchers with University College London, Johns Hopkins University and the University of Toronto assiste...
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tu... Background Veliparib is a potent small molecule inhibitor of PARP-1/2, which is cytotoxic in tumor cells with deficiencies in BRCA1 or ...